1. Home
  2. NCNO vs CELC Comparison

NCNO vs CELC Comparison

Compare NCNO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NCNO
  • CELC
  • Stock Information
  • Founded
  • NCNO 2011
  • CELC 2011
  • Country
  • NCNO United States
  • CELC United States
  • Employees
  • NCNO N/A
  • CELC N/A
  • Industry
  • NCNO Computer Software: Prepackaged Software
  • CELC Medical Specialities
  • Sector
  • NCNO Technology
  • CELC Health Care
  • Exchange
  • NCNO Nasdaq
  • CELC Nasdaq
  • Market Cap
  • NCNO 3.0B
  • CELC 3.1B
  • IPO Year
  • NCNO 2020
  • CELC 2017
  • Fundamental
  • Price
  • NCNO $24.68
  • CELC $98.95
  • Analyst Decision
  • NCNO Buy
  • CELC Strong Buy
  • Analyst Count
  • NCNO 17
  • CELC 7
  • Target Price
  • NCNO $34.40
  • CELC $95.29
  • AVG Volume (30 Days)
  • NCNO 1.8M
  • CELC 895.4K
  • Earning Date
  • NCNO 12-03-2025
  • CELC 11-12-2025
  • Dividend Yield
  • NCNO N/A
  • CELC N/A
  • EPS Growth
  • NCNO N/A
  • CELC N/A
  • EPS
  • NCNO N/A
  • CELC N/A
  • Revenue
  • NCNO $573,119,000.00
  • CELC N/A
  • Revenue This Year
  • NCNO $10.88
  • CELC N/A
  • Revenue Next Year
  • NCNO $8.53
  • CELC N/A
  • P/E Ratio
  • NCNO N/A
  • CELC N/A
  • Revenue Growth
  • NCNO 13.24
  • CELC N/A
  • 52 Week Low
  • NCNO $18.75
  • CELC $7.58
  • 52 Week High
  • NCNO $42.88
  • CELC $103.06
  • Technical
  • Relative Strength Index (RSI)
  • NCNO 42.58
  • CELC 76.82
  • Support Level
  • NCNO $23.90
  • CELC $92.10
  • Resistance Level
  • NCNO $25.20
  • CELC $96.10
  • Average True Range (ATR)
  • NCNO 0.80
  • CELC 5.41
  • MACD
  • NCNO -0.10
  • CELC 0.90
  • Stochastic Oscillator
  • NCNO 26.91
  • CELC 86.23

About NCNO nCino Inc.

Ncino Inc is a provider of cloud-based software for financial institutions. Its software solution digitizes, automates, and streamlines inefficient and complex processes & workflows and utilizes data analytics & artificial intelligence that enables financial institutions to onboard new clients, make loans, and manage the entire loan life cycle, open deposits, and other accounts, and manage regulatory compliance. It also offers professional services, including configuration & implementation, training, and advisory services. The company generates the majority of its revenue from subscription services. The company caters to financial institutions, enterprise banks, regional banks, community banks, and credit unions. The vast majority of its revenue comes from the United States.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: